<DOC>
	<DOCNO>NCT02465138</DOCNO>
	<brief_summary>Determine IV ketorolac effective agent prevention post-ERCP pancreatitis . Determine IV ketorolac provide improved post-procedure analgesia . Determine systemic mediator inflammation reduce patient receive IV ketorolac follow ERCP .</brief_summary>
	<brief_title>A Randomized Controlled Trial IV Ketorolac Prevent Post-ERCP Pancreatitis</brief_title>
	<detailed_description>Acute pancreatitis common major complication diagnostic therapeutic endoscopic retrograde cholangiopancreatography ( ERCP ) , account substantial morbidity annual expenditure approximately 150 million annually . ( 1,2 ) Non-steroidal anti-inflammatory agent ( NSAIDs ) show effective multiple prospective randomize control trial prevention post-ERCP pancreatitis . ( 3-6 ) NSAIDs postulate inhibit phospholipase A2 prostaglandin synthesis , play important role inflammatory cascade acute pancreatitis . Rectal suppository indomethacin ( potent COX-2 inhibitor ) effective prevent post-ERCP pancreatitis clinical trial recommend routine use ERCP European Society Gastrointestinal Endoscopy . ( 7 ) ToradolÂ® ( ketorolac ) , NSAID available IV form , potent COX-2 inhibitor analgesic indomethacin . ( 8,9 ) Ketorolac routinely use postoperatively follow major surgery assist pain control particularly follow orthopedic procedure . IV ketorolac never evaluate prevention post-ERCP pancreatitis .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>All patient present SFGH ERCP Age 1885 Do meet exclusion criterion Acute pancreatitis time ERCP Use NSAIDs previous week Peptic ulcer disease Severe renal dysfunction Pregnancy Lithium therapy allergy ketorolac</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>